Lupin receives FDA approval for biosimilar Armlupeg

Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

Exyte completes Pharmaplan integration

Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division

GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma

GV20 received an upfront payment and is eligible for additional milestone payments

Cidara hits target enrollment for Phase 3 flu trial ahead of peak season

CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents

Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub

The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre

Thermo Fisher opens two new centers in Hyderabad

The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi

Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis

GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal

GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies

The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy